Roger P, Gascard J P, Bara J, de Montpreville V T, Brink C
Laboratoire de Pharmacologie Pulmonaire, CNRS-ESA 8078, H pital Marie Lannelongue, Le Plessis Robinson, France.
Mediators Inflamm. 2001 Feb;10(1):33-6. doi: 10.1080/09629350124329.
Increased secretion of mucus is a hallmark of many respiratory diseases and contributes significantly to the airflow limitation experienced by many patients. While the current pharmacological approach to reducing mucus and sputum production in patients is limited, clinical studies have suggested that drugs which inhibit the cyclooxygenase and/or 5-lipoxygenase enzymatic pathways may reduce secretory activity in patients with airway disease.
This study was performed to investigate the effects of indomethacin (cyclooxygenase inhibitor) and Bay x 1005 (5-lipoxygenase inhibitor) on MUC5AC release from human airways in vitro.
An immunoradiometric assay was used to determine the quantities of MUC5AC present in the biological fluids derived from human airways in vitro. The measurements were made with a mixture of eight monoclonal antibodies (MAbs; PM8) of which the 21 M1 MAb recognized a recombinant M1 mucin partially encoded by the MUC5AC gene.
The quantities of MUC5AC detected in the biological fluids derived from human bronchial preparations were not modified after treatment with indomethacin (cyclooxygenase inhibitor) and/or an inhibitor of the 5-lipoxygenase metabolic pathway (BAY x 1005).
These results suggest that the cyclooxygenase and 5-lipoxygenase metabolic pathways play little or no role in the release of MUC5AC from human airways.
黏液分泌增加是许多呼吸道疾病的一个标志，并且是导致许多患者气流受限的重要因素。虽然目前用于减少患者黏液和痰液生成的药理学方法有限，但临床研究表明，抑制环氧化酶和/或5-脂氧合酶酶促途径的药物可能会降低气道疾病患者的分泌活性。
本研究旨在调查吲哚美辛（环氧化酶抑制剂）和Bay x 1005（5-脂氧合酶抑制剂）对体外人气道MUC5AC释放的影响。
采用免疫放射分析法定量测定体外人气道生物流体中MUC5AC的含量。测量使用了八种单克隆抗体（MAb；PM8）的混合物，其中21 M1 MAb识别由MUC5AC基因部分编码的重组M1黏蛋白。
用吲哚美辛（环氧化酶抑制剂）和/或5-脂氧合酶代谢途径抑制剂（BAY x 1005）处理后，人支气管制剂生物流体中检测到的MUC5AC含量未发生改变。
这些结果表明，环氧化酶和5-脂氧合酶代谢途径在人气道MUC5AC释放中作用很小或没有作用。
